Oragenics, Inc. (OGEN) |
1.09 0 (0%) 04-24 13:55 |
Open: | 1.11 |
High: | 1.11 |
Low: | 1.065 |
Volume: | 9,180 |
Market Cap: | 5(M) |
PE Ratio: | -0.24 |
Exchange: | American Stock Exchange |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 1.49 |
Resistance 1: | 1.31 |
Pivot price: | 1.17 |
Support 1: | 1.01 |
Support 2: | 0.84 |
52w High: | 7.74 |
52w Low: | 1.01 |
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
EPS | -10370000.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | -182.600 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -28.00 |
Return on Assets (ttm) | 53.1 |
Return on Equity (ttm) | -52.1 |
Fri, 19 Apr 2024
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - Business Wire
Mon, 01 Apr 2024
Oragenics, Inc. Files 10K and Provides Company Update - Business Wire
Fri, 01 Mar 2024
Oragenics Inc Enhances Financial Standing with Equity Sale - TipRanks.com - TipRanks
Wed, 28 Feb 2024
Oragenics Inc Announces Proposed Public Stock Offering - TipRanks.com - TipRanks
Wed, 28 Feb 2024
Oragenics Inc Announces Public Offering Pricing Details - TipRanks.com - TipRanks
Wed, 28 Feb 2024
Why Is Oragenics (OGEN) Stock Down 45% Today? - InvestorPlace
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |